Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X about a paper he co-authored with colleagues published in ESMO Gastrointestinal Oncology:
“Pleased to share our ongoing phase II TNT protocol (FLOT, pembro, short RT) for resectable GEJ adenocarcinoma, integrating whole-genome ctDNA to support clinical CR-based organ preservation.”
Title: An open label phase II study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally advanced gastroesophageal junction adenocarcinoma (EPOC2301)
Authors: K. Sato, I. Nakayama, M. Yura, A. Sato, M. Suzuki, T. Kadota, M. Nakamura, N. Sakamoto, T. Hashimoto, S. Sakashita, M. Wakabayashi, H. Shoji, T. Hayashi, H. Daiko, K. Kato, T. Yoshino, T. Yano, T. Fujita, T. Kinoshita, K. Shitara
Read the Full Article in ESMO Gastrointestinal Oncology.
More posts featuring Kohei Shitara.
